
Shares of generic drugmaker Viatris VTRS.O rise 3.9% to $9.09 premarket
VTRS posts Q2 adj. profit of 62 cents per share compared with analysts' estimate of 56 cents - data compiled by LSEG
Its quarterly revenue came in at $3.58 billion vs estimates of $3.47 billion
Company reaffirms its 2025 revenue forecast to be between $13.5 billion and $14 billion
Also reaffirms its annual adj. profit per share to be between $2.16 and $2.30
Up to last close, stock was down 29.7% YTD